Untargeted Metabolomics for Autism Spectrum Disorders: Current Status and Future Directions

• Main Authors: Kevin E. Glinton, Sarah H. Elsea
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2019-09-01
• Series: Frontiers in Psychiatry
• Subjects: autism; untargeted metabolomics; inborn errors of metabolism; metabolome; mass spectrometry; nuclear magnetic resonance spectroscopy
• Online Access: https://www.frontiersin.org/article/10.3389/fpsyt.2019.00647/full

Autism spectrum disorders (ASDs) are a group of neurodevelopment disorders characterized by childhood onset deficits in social communication and interaction. Although the exact etiology of most cases of ASDs is unknown, a portion has been proposed to be associated with various metabolic abnormalities including mitochondrial dysfunction, disorders of cholesterol metabolism, and folate abnormalities. Targeted biochemical testing like plasma amino acid and acylcarnitine profiles have demonstrated limited utility in helping to diagnose and manage such patients. Untargeted metabolomics has emerged, however, as a promising tool in screening for underlying biochemical abnormalities and managing treatment and as a means of investigating possible novel biomarkers for the disorder. Here, we review the principles and methodology behind untargeted metabolomics, recent pilot studies utilizing this technology, and areas in which it may be integrated into the care of children with this disorder in the future.